莫西沙星联合信必可都保对AECOPD疗效及免疫炎症反应的影响  

Effect of moxifloxacin combined with symbicort turbuhaler on the efficacy and immune inflammatory response of AECOPD

作　　者：赵艳敏 于小杰[1] 王娜[1] 牛春密 ZHAO Yanmin;YU Xiaojie;WANG Na;NIU Chunmi(Pharmaceutical Preparation Section,Qinhuangdao First Hospital,Qinhuangdao 066000,Hebei,China)

机构地区：[1]秦皇岛市第一医院药剂科,河北省秦皇岛市066000

出　　处：《中南医学科学杂志》2022年第6期902-905,共4页Medical Science Journal of Central South China

基　　金：秦皇岛市重点研发计划科技支撑项目(201902A092)。

摘　　要：目的探讨莫西沙星联合信必可都保对慢性阻塞性肺疾病急性加重期(AECOPD)疗效及免疫炎症反应的影响。方法AECOPD患者130例按用药情况分为莫西沙星组42例,信必可都保组41例和联合组47例。比较各组治疗前后临床疗效、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC],以及二氧化碳分压(PaCO_(2))、氧分压(PaO_(2))、免疫球蛋白IgG、IgA、IgM、血清环氧化酶-2(COX-2)、前列腺素E2(PGE2)和不良反应情况。结果联合组总有效率高于莫西沙星组和信必可都保组(P<0.05)。与治疗前比较,各组治疗后FVC、FEV1、FEV1/FVC、PaO_(2)、IgG、IgA、IgM升高,PaCO_(2)、COX-2、PGE2降低(P<0.05),且联合组改善更为明显(P<0.05)。各组不良反应总发生率差异无显著性(P>0.05)。结论莫西沙星联合信必可都保治疗AECOPD可提高临床疗效,增强患者免疫功能,值得临床推广。Aim To investigate the effect of moxifloxacin combined with symbicort turbuhaler on the curative effect and immune inflammatory reaction of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods 130 patients with AECOPD were divided into moxifloxacin group(42 cases),symbicort turbuhaler group(41 cases)and combination group(47 cases).The clinical efficacy,pulmonary function indexes(forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),FEV1/FVC),partial pressure of carbon dioxide(PaCO_(2)),partial pressure of oxygen(PaO_(2)),immunoglobulin IgG,IgA,IgM,serum cyclooxygenase-2(COX-2),prostaglandin E2(PGE2)and adverse reactions were compared before and after treatment in each group.Results The total effective rate of the combined group was higher than moxifloxacin group and symbicort turbuhaler group(P<0.05).Compared with that before treatment,FVC,FEV1,FEV1/FVC,PaO_(2),IgG,IgA and IgM increased,PaCO_(2),COX-2 and PGE2 were decreased in each group after treatment(P<0.05),and the improvement was more obvious in the combined group(P<0.05).There was no significant difference in the total incidence of adverse reactions among the groups(P>0.05).Conclusion Moxifloxacin combined with symbicort turbuhaler in the treatment of AECOPD can improve the clinical efficacy and enhance the immune function of patients,which is worthy of clinical promotion.

关 键 词：莫西沙星 信必可都保 慢性阻塞性肺疾病 免疫球蛋白 环氧化酶-2 前列腺素E2 

分 类 号：R974[医药卫生—药品]